Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TXN | P10599 | 1/20 | 0.82 |
| ▸ | APP | P05067 | 3/20 | 0.65 |
| ▸ | MAPT | P10636 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.59 |
| ▸ | KCNH3 | Q9ULD8 | 5/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 2/20 | 0.56 |
| ▸ | CA1 | P00915 | 2/20 | 0.56 |
| ▸ | CA2 | P00918 | 2/20 | 0.56 |
| ▸ | CA9 | Q16790 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.51 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.51 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1658574 | 0.96 | TXN (0.89) | TXNAPPMAPTMEN1KMT2A | |
| SCHEMBL21645541 | 0.96 | TXN (0.89) | TXNAPPMAPTMEN1KMT2A | |
| SCHEMBL1925527 | 0.93 | MEN1 (0.79) | TXNAPPMAPTMEN1KMT2A | |
| SCHEMBL28736406 | 0.91 | TXN (0.70) | TXNAPPMAPTMEN1KMT2A | |
| SCHEMBL1924287 | 0.91 | APP (0.70) | TXNAPPMAPTMEN1KMT2A | |
| SCHEMBL20511159 | 0.90 | TXN (1.00) | TXNAPPMAPTMEN1KMT2A | |
| SCHEMBL11837292 | 0.84 | NFKB1 (0.78) | TXNAPPMAPTMEN1KMT2A | |
| SCHEMBL15720066 | 0.84 | NR1I2 (0.78) | TXNAPPMAPTKMT2AKCNH3 | |
| SCHEMBL21645364 | 0.83 | GAA (0.68) | TXNAPPMAPTMEN1KMT2A | |
| SCHEMBL13950835 | 0.83 | TXN (0.64) | TXNAPPMAPTSMN1; SMN2NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399663-B2 | Salt of 1,3,5-triazine-2,4,6-triamine derivative | ASTELLAS PHARMA INC. (JP) | 2013-03-19 | — | — | US | disclosed |
| US-20120202814-A1 | COMPOUNDS WITH DDX3 INHIBITORY ACTIVITY AND USES THEREOF | UNIVERSITÀ DEGLI STUDI DI SIENA (IT) | 2012-08-09 | — | — | US | disclosed |
| US-20120202814-A1 | COMPOUNDS WITH DDX3 INHIBITORY ACTIVITY AND USES THEREOF | UNIVERSITÀ DEGLI STUDI DI SIENA (IT) | 2012-08-09 | — | — | US | disclosed |
| US-20120202814-A1 | COMPOUNDS WITH DDX3 INHIBITORY ACTIVITY AND USES THEREOF | UNIVERSITÀ DEGLI STUDI DI SIENA (IT) | 2012-08-09 | — | — | US | disclosed |
| EP-2414351-A1 | NOVEL SALT OF 1,3,5-TRIAZINE-2,4,6-TRIAMINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2012-02-08 | — | — | EP | disclosed |
| EP-2413940-A1 | COMPOSITIONS COMPRISING 2, 4, 6-TRIAMINO-1, 3, 5-TRIAZINE DERIVATIVES FOR TREATMENT OF SCHIZOPHRENIA | Astellas Pharma Inc. (JP) | 2012-02-08 | — | — | EP | disclosed |
| WO-2011039735-A2 | COMPOUNDS WITH DDX3 INHIBITORY ACTIVITY AND USES THEREOF | CONSIGLIO NAZIONALE DELLE RICERCHE (IT) | 2011-04-07 | — | — | WO | disclosed |
| US-20100256151-A1 | NOVEL SALT OF 1,3,5-TRIAZINE-2,4,6-TRIAMINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
| WO-2010114163-A1 | COMPOSITIONS COMPRISING 2, 4, 6-TRIAMINO-1, 3, 5-TRIAZINE DERIVATIVES FOR TREATMENT OF SCHIZOPHRENIA | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | WO | disclosed |
| WO-2010114162-A1 | NOVEL SALT OF 1,3,5-TRIAZINE-2,4,6-TRIAMINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | WO | disclosed |
| US-20100256152-A1 | NOVEL PHARMACEUTICAL COMPOSITION FOR TREATMENT OF SCHIZOPHRENIA | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
| US-3931165-A | INSECTICIDES, HERBICIDES | BARER SOL J | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202814-A1 | COMPOUNDS WITH DDX3 INHIBITORY ACTIVITY AND USES THEREOF | DDX3X, DDX21, DDX39B | TXN 2465/4885APP 3458/4885MAPT 4074/4885 |
| US-20100256152-A1 | NOVEL PHARMACEUTICAL COMPOSITION FOR TREATMENT OF SCHIZOPHRENIA | KCNAB1, KCNN1, SCN1A | TXN 3164/4885APP 1715/4885MAPT 723/4885 |
| US-20100256151-A1 | NOVEL SALT OF 1,3,5-TRIAZINE-2,4,6-TRIAMINE DERIVATIVE | FH, FAH, GOT1 | TXN 1640/4885APP 3174/4885MAPT 391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.